These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 7501145)
1. Cognitive performance on the Alzheimer's Disease Assessment Scale: effect of education. Doraiswamy PM; Krishen A; Stallone F; Martin WL; Potts NL; Metz A; DeVeaugh-Geiss J Neurology; 1995 Nov; 45(11):1980-4. PubMed ID: 7501145 [TBL] [Abstract][Full Text] [Related]
2. The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Doraiswamy PM; Bieber F; Kaiser L; Krishnan KR; Reuning-Scherer J; Gulanski B Neurology; 1997 Jun; 48(6):1511-7. PubMed ID: 9191757 [TBL] [Abstract][Full Text] [Related]
3. [Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project]. Monllau A; Pena-Casanova J; Blesa R; Aguilar M; Bohm P; Sol JM; Hernandez G Neurologia; 2007 Oct; 22(8):493-501. PubMed ID: 17602338 [TBL] [Abstract][Full Text] [Related]
4. The validity and reliability of the Turkish version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild and moderate Alzheimer's disease and normal subjects. Mavioglu H; Gedizlioglu M; Akyel S; Aslaner T; Eser E Int J Geriatr Psychiatry; 2006 Mar; 21(3):259-65. PubMed ID: 16477580 [TBL] [Abstract][Full Text] [Related]
5. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease. Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431 [TBL] [Abstract][Full Text] [Related]
6. An Arabic Version of the Cognitive Subscale of the Alzheimer's Disease Assessment Scale (ADAS-Cog): Reliability, Validity, and Normative Data. Ben Jemaa S; Attia Romdhane N; Bahri-Mrabet A; Jendli A; Le Gall D; Bellaj T J Alzheimers Dis; 2017; 60(1):11-21. PubMed ID: 28505978 [TBL] [Abstract][Full Text] [Related]
7. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? Benge JF; Balsis S; Geraci L; Massman PJ; Doody RS Dement Geriatr Cogn Disord; 2009; 28(1):63-9. PubMed ID: 19641319 [TBL] [Abstract][Full Text] [Related]
8. The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease. Doraiswamy PM; Kaiser L; Bieber F; Garman RL Alzheimer Dis Assoc Disord; 2001; 15(4):174-83. PubMed ID: 11723368 [TBL] [Abstract][Full Text] [Related]
10. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response. Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450 [TBL] [Abstract][Full Text] [Related]
11. [Validation of the Hungarian version of Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) in patients with mild cognitive impairment]. Papp E; Pákáski M; Drótos G; Kálmán J Psychiatr Hung; 2012; 27(6):426-34. PubMed ID: 23429337 [TBL] [Abstract][Full Text] [Related]
12. The cognitive subscale of the "Alzheimer's Disease Assessment Scale" in a Brazilian sample. Schultz RR; Siviero MO; Bertolucci PH Braz J Med Biol Res; 2001 Oct; 34(10):1295-302. PubMed ID: 11593304 [TBL] [Abstract][Full Text] [Related]
13. Item analysis of ADAS-Cog: effect of baseline cognitive impairment in a clinical AD trial. Sevigny JJ; Peng Y; Liu L; Lines CR Am J Alzheimers Dis Other Demen; 2010 Mar; 25(2):119-24. PubMed ID: 19949163 [TBL] [Abstract][Full Text] [Related]
14. What is the clinically relevant change on the ADAS-Cog? Schrag A; Schott JM; J Neurol Neurosurg Psychiatry; 2012 Feb; 83(2):171-3. PubMed ID: 22019547 [TBL] [Abstract][Full Text] [Related]
15. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Mecocci P; Bladström A; Stender K Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640 [TBL] [Abstract][Full Text] [Related]
16. How Do Scores on the ADAS-Cog, MMSE, and CDR-SOB Correspond? Balsis S; Benge JF; Lowe DA; Geraci L; Doody RS Clin Neuropsychol; 2015; 29(7):1002-9. PubMed ID: 26617181 [TBL] [Abstract][Full Text] [Related]
17. Real-World, Multinational, Retrospective Observational Survey of the ADAS-Cog and Associations with Healthcare Resource Utilization in Patients with Alzheimer's Disease. Ritchie CW; Khandker RK; Pike J; Black CM; Jones E; Ambegaonkar BM J Alzheimers Dis; 2018; 64(3):899-910. PubMed ID: 29966202 [TBL] [Abstract][Full Text] [Related]
18. The characteristics of patients with uncertain/mild cognitive impairment on the Alzheimer disease assessment scale-cognitive subscale. Pyo G; Elble RJ; Ala T; Markwell SJ Alzheimer Dis Assoc Disord; 2006; 20(1):16-22. PubMed ID: 16493231 [TBL] [Abstract][Full Text] [Related]
19. Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. Kennedy J; Deberdt W; Siegal A; Micca J; Degenhardt E; Ahl J; Meyers A; Kaiser C; Baker RW Int J Geriatr Psychiatry; 2005 Nov; 20(11):1020-7. PubMed ID: 16250069 [TBL] [Abstract][Full Text] [Related]
20. Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s' Perceptions. Meyer SM; Bertzos KA; Perez M; Connor DJ; Schafer K; Walter S Curr Alzheimer Res; 2017; 14(9):1008-1016. PubMed ID: 28413982 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]